ROCKVILLE, Md. — NeoImmuneTech, Inc. (NIT), a global leader in T-cell-based immunotherapy, today presented a poster on a pre-clinical study that opens a new field of potential applications for NT-I7 (efineptakin alfa). The poster was presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting. The study explored...
treatment News
NERVIANO, IT and BOSTON, Mass. – Nerviano Medical Sciences S.r.l. (NMS), a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc. (NMS-US), a wholly owned subsidiary of NMS Group, focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, announced...
SAN DIEGO, CA — Neuralace Medical, Inc., an innovator in pain management technology, today proudly announces the FDA clearance of its groundbreaking product, Axon Therapy (mPNS), for the treatment of chronic Painful Diabetic Neuropathy (PDN). This landmark approval marks the first-ever FDA clearance of a non-invasive, magnetic peripheral nerve stimulation (mPNS)...
WAYNE, Pa. — Neuraptive Therapeutics Inc., a leader in innovative medical solutions, is pleased to announce that it has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for its fusogen contained in the NTX-001 treatment kit. This designation marks a significant milestone in developing NTX-001, a...
MELBOURNE, Australia — Neuren Pharmaceuticals Limited today announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Phelan-McDermid syndrome (PMS). Significant improvement was observed by both clinicians and caregivers from treatment, across multiple efficacy measures. Improvements were consistently seen across many of the core PMS characteristics....
MONTREAL, Québec — Neurenati Therapeutics is delighted to announce the successful closing of its seed funding round, securing 1.2 million $ from Genson Capital, on the 2024 Rare Disease Day. Neurenati, a Québec-based biotech company, focuses on the development of various rare diseases therapies, including pediatric conditions. Combined with the...
SCHLIEREN, Switzerland – AL-S Pharma AG, a biotech company jointly founded by Neurimmune and TVM Capital Life Science, announced today enrollment of the first patient in a multicenter, placebo-controlled Phase 2 clinical trial to evaluate AP-101 in patients with amyotrophic lateral sclerosis (ALS). AP-101 is a human antibody directed against misfolded...
CAMBRIDGE, Mass. — NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the completion of enrollment of Part 1 of its two-part, Phase 2a clinical trial evaluating the efficacy and safety, of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist for the treatment...
– Highly Statistically Significant Reduction in Chorea Movements (p < 0.0001) as Measured by the Unified Huntington’s Disease Rating Scale (UHDRS®) Total Maximal Chorea (TMC) Score – Placebo-Adjusted Mean Reduction in TMC Score of 3.2 Units in Valbenazine-Treated Patients – Company Plans to Submit Supplemental New Drug Application to U.S....
SAN DIEGO, Calif. — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved INGREZZA® SPRINKLE (valbenazine) capsules, a new oral granules formulation of INGREZZA® (valbenazine) capsules prescribed for the treatment of adults with tardive dyskinesia and chorea associated with Huntington’s disease. INGREZZA SPRINKLE provides...